Skip to main content

Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT)

Tipranks - Tipranks - Sat Feb 7, 10:58AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mettler-Toledo (MTD – Research Report) and Abbott Laboratories (ABT – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Mettler-Toledo (MTD)

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Mettler-Toledo today. The company’s shares closed last Friday at $1363.81.

According to TipRanks.com, Ryskin is a 4-star analyst with an average return of 4.4% and a 56.2% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Mettler-Toledo is a Moderate Buy with an average price target of $1502.71, an 8.6% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $1550.00 price target.

See today’s best-performing stocks on TipRanks >>

Abbott Laboratories (ABT)

TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories today and set a price target of $137.00. The company’s shares closed last Friday at $109.88.

According to TipRanks.com, Jennings is a 4-star analyst with an average return of 4.9% and a 49.3% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $138.76 average price target, implying a 26.0% upside from current levels. In a report issued on January 22, RBC Capital also maintained a Buy rating on the stock with a $135.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).